Articles citing this paper
Delays in access to affordable medicines: putting policy into perspective
Alison Pearce A B , Kees van Gool A , Philip Haywood A and Marion Haas A
+ Author Affiliations
- Author Affiliations
A Centre for Health Economics Research and Evaluation, University of Technology, PO Box 123, Broadway, NSW 2007, Australia. Emails: kees.vangool@chere.uts.edu.au, phil.haywood@chere.uts.edu.au, marion.haas@chere.uts.edu.au
B Corresponding author. Email: alison.pearce@chere.uts.edu.au
Australian Health Review 36(4) 412-418 https://doi.org/10.1071/AH11110
Submitted: 8 November 2011 Accepted: 19 April 2012 Published: 15 October 2012
12 articles found in Crossref database.
Delays in access to affordable medicines: putting policy into perspective – authors’ response
Pearce Alison M.,
van Gool Kees,
Haywood Philip, Haas Marion
Australian Health Review. 2014 38(1). p.16
Comparison of New Drug Accessibility and Price Between Japan and Major European Countries
Takayama Akane, Narukawa Mamoru
Therapeutic Innovation & Regulatory Science. 2017 51(5). p.604
Private Health Insurance (2020)
Private Health Insurance (2020)
Promoting the personal importation of therapeutic goods: recent legislative amendments to advertising regulations may impact consumer access and understanding
Rudge Christopher, Ghinea Narcyz
Australian Health Review. 2023 47(2). p.182
Patient access to medicines in two countries with similar health systems and differing medicines policies: Implications from a comprehensive literature review
Babar Zaheer- Ud-Din,
Gammie Todd,
Seyfoddin Ali,
Hasan Syed Shahzad, Curley Louise E.
Research in Social and Administrative Pharmacy. 2019 15(3). p.231
Delays in access to affordable medicines: putting policy into perspective
Wonder Michael, Chin Geoffrey
Australian Health Review. 2013 37(4). p.430
Pharmaceutical Pricing and Reimbursement in Japan: For Faster, More Complete Access to New Drugs
Takayama Akane, Narukawa Mamoru
Therapeutic Innovation & Regulatory Science. 2016 50(3). p.361
Delayed access to treatments for rare diseases: Who's to blame?
Feltmate Karen,
Janiszewski Peter M.,
Gingerich Sheena, Cloutier Michael
Respirology. 2015 20(3). p.361
Affordability Assessment from a Static to Dynamic Concept: A Scenario-Based Assessment of Cardiovascular Medicines
Zarei Leila,
Karimzadeh Iman,
Moradi Najmeh,
Peymani Payam,
Asadi Sara, Babar Zaheer-Ud-Din
International Journal of Environmental Research and Public Health. 2020 17(5). p.1710
Reimbursement Lag of New Drugs Under Taiwan's National Health Insurance System Compared With United Kingdom, Canada, Australia, Japan, and South Korea
Shih Yi‐Ru,
Liao Kai‐Hsin,
Chen Yen‐Hui,
Lin Fang‐Ju, Hsiao Fei‐Yuan
Clinical and Translational Science. 2020 13(5). p.916
Improving Interactions Between Health Technology Assessment Bodies and Regulatory Agencies: A Systematic Review and Cross-Sectional Survey on Processes, Progress, Outcomes, and Challenges
Ofori-Asenso Richard,
Hallgreen Christine E., De Bruin Marie Louise
Frontiers in Medicine. 2020 7
